Skip to content

Gene Therapy

Explores the principles and applications of gene therapy, including techniques, ethical considerations, and clinical case studies. Designed to help students prepare for exams.

30 questions

One limitation of in vivo gene therapy is:

Direct in vivo administration viral vectors faces major limitation reduced control which cells internalize vector genome achieve therapeutic expression compared ex vivo selection. Systemic IV infusion distributes AAV particles according cardiac output vascular permeability liver sinusoidal fenestrations 100 nm capturing ~90 percent dose via heparan sulfate proteoglycan uptake hepatocytes Kupffer macrophages while target skeletal myofibers CNS neurons behind blood-brain barrier differentiated airway epithelia receive subtherapeutic copy numbers below threshold efficacy. No selection feasible af

Ref: Molecular Therapy In Vivo Targeting Limitations 2021; FDA Guidance In Vivo Gene Therapy Low Control Challenges; Lodish Gene Delivery Biodistribution Barriers Chap 9.

Antisense therapy blocks gene expression at level of:

Antisense strategy modulates gene expression multiple stages RNA metabolism not protein folding secretion downstream. Design involves complementary oligonucleotide binding pre-mRNA sequences within 5 prime splice donor GU branch point adenosine polypyrimidine tract exonic splicing enhancer ESE purine-rich recognized SR proteins altering spliceosome U1 U2 snRNP assembly dictating alternative splicing outcomes enabling exon 7 inclusion SMN2 or exon 51 skipping dystrophin restoring open reading frame disrupted deletion. Binding 5 prime 7-methylguanosine cap AUG start codon context Kozak sequence

Ref: Nature Rev Drug Disc Antisense Transcription Translation Blockade 2020; FDA Antisense Mechanism Guidance; Alberts RNA Processing Antisense Regulation Chap 8.

Factor VIII gene is large because it contains:

F8 gene locus Xq28 spans 186 kb making one largest human genes underlying hemophilia A. Coding sequence organized 26 exons ranging 69 bp smallest exon 5 to 3106 bp exon 14 encoding central B domain separated 25 introns some >30 kb enriched Alu retrotransposon repeats 35 copies LINE1 causing genomic instability. Intron 22 contains 9.5 kb inverted repeat int22h harboring internal genes F8A novel transcript unknown function F8B small protein antisense FVIII plus CpG island. Homologous recombination intrachromosomal int22h within intron 22 extragenic telomeric copies 500 kb distal causes inversion

Ref: NCBI Gene F8 Genomic Structure 186kb Map; Nature Genet Hemophilia Intron 22 Inversion; Watson Molecular Biology Large Genes Chap 6.

Factor VIII recombinant protein is commonly produced in:

Coagulation factor VIII complex multidomain glycoprotein organized signal peptide 19 residues followed domains A1 a1 A2 a2 B a3 A3 C1 C2 totaling 2351 aa 280 kDa requiring extensive co-translational post-translational processing secretory pathway. Nascent polypeptide translocates Sec61 translocon ER lumen signal peptidase cleaves signal oligosaccharyltransferase adds high-mannose oligosaccharides 25 asparagine X Ser Thr motifs protein disulfide isomerase forms 8 disulfide bonds calnexin calreticulin cycle glucosidase II monitors folding peptidyl prolyl isomerase assists. Golgi further trims ma

Ref: Blood Factor VIII CHO Production Kaufman 1988; FDA Recombinant Factor VIII Manufacturing Guidelines; Alberts Protein Glycosylation Mammalian Cells Chap 15.

Somatostatin is produced as:

Somatostatin tetradecapeptide 14 aa sequence Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys cyclized via disulfide cysteines 3 and 14 functions potent inhibitor growth hormone insulin glucagon secretion, making direct bacterial expression challenging small bioactive peptide inserts membrane disrupts host metabolism undergoes rapid proteolysis cytoplasmic peptidases OmpT. To overcome instability Itakura 1977 expressed synthetic DNA encoding somatostatin fused downstream E. coli beta-galactosidase fragment 590 residues or tryptophan operon leader peptide trpE 190 residues under trp prom

Ref: Itakura et al Science 1977 Somatostatin Fusion Production Landmark; NCBI First Recombinant Peptide Manufacturing Review; Lodish Fusion Protein Expression Chap 9.

Human growth hormone is produced using:

Human growth hormone somatotropin monomeric 22 kDa protein 191 aa two intramolecular disulfide bridges Cys53-Cys165 Cys182-Cys189 secreted somatotrophs anterior pituitary under GHRH stimulates hepatic IGF-1 production promoting longitudinal bone growth protein synthesis. Recombinant production first accomplished E. coli K12 because hormone lacks N-linked glycosylation essential in vivo activity unlike erythropoietin requiring sialylated glycans circulatory half-life, making prokaryotic expression feasible cost-effective. Gene without native signal peptide inserted downstream tryptophan operon

Ref: Endocrine Reviews hGH E coli Production Goeddel 1979; NCBI Biotech hGH Manufacturing Process; Campbell Recombinant Expression Systems Ch 20.

Cyanogen bromide is used in insulin production to:

Cyanogen bromide chemical cleavage exquisite selectivity methionine residues enabling precise excision fusion partner. Mechanism involves nucleophilic attack thioether sulfur methionine electrophilic carbon CNBr generating cyanosulfonium intermediate undergoing intramolecular cyclization carbonyl oxygen forming iminolactone ring subsequently hydrolyzed acidic conditions homoserine lactone C-terminal cleavage site while N-terminal fragment released. Specificity exploited recombinant insulin manufacturing where fusion proteins engineered single methionine codon junction between beta-galactosidas

Ref: Methods Enzymol Cyanogen Bromide Cleavage Meinke 1981; Watson Molecular Biology Protein Cleavage Methods; NCERT Biotechnology Bioprocess Cleavage Techniques.

Recombinant insulin production involves fusion with:

Early industrial production human insulin 1982 relied fusion protein technology because small 51 aa insulin A 21 B 30 rapidly degraded bacterial cytoplasm proteases Lon Clp if expressed mature alone. Genentech team Riggs Boyer Goeddel chemically synthesized DNA encoding insulin chains separately fused carboxy terminus E. coli beta-galactosidase 1024 aa enzyme encoded lacZ or trp leader peptide. Large fusion drove formation insoluble inclusion bodies protecting heterologous peptide from proteolysis enabling purification centrifugation detergent washes. Construct single methionine codon junction

Ref: Science History Institute Recombinant Insulin LacZ Fusion 1982; NCBI Bookshelf Insulin Fusion Production; Goeddel et al PNAS 1979 Insulin Expression.

Target cells in cardiovascular gene therapy include:

Endothelial cell central therapeutic target cardiovascular gene therapy because monolayer regulates vascular homeostasis via eNOS converting L-arginine to nitric oxide stimulating soluble guanylate cyclase raising cGMP relaxing smooth muscle, prostacyclin via COX2 inhibiting platelet aggregation, barrier integrity VE-cadherin junctions, leukocyte adhesion E-selectin VCAM1. Dysfunction oxidative stress uncoupling eNOS drives atherosclerosis hypertension ischemia. Ischemic peripheral artery disease refractory angina benefit proangiogenic factors VEGF-A165, FGF4, HGF, HIF1-alpha delivered AAV1 or

Ref: Circ Res Cardiovascular Gene Therapy Endothelial Targets 2022; NHLBI Vascular Gene Therapy Overview; Lodish Vascular Biology Endothelial Function Chap 22.

Cancer gene therapy often uses strategy of:

Cancer gene therapy predominantly adopts tumoricidal strategy rather than restoration tumor suppressor because cancer genome carries multiple gain-of-function oncogenes KRAS MYC aneuploidy heterogeneity complicating simple addition. Methods eliminate malignant clone through introduction genes triggering death or immune recruitment. Oncolytic adenoviruses engineered deletion E1B 55 kDa protein normally inactivating p53 replicate selectively p53-deficient cancers lysing cells via viral burst releasing PAMPs tumor antigens danger signals ATP calreticulin HMGB1 driving immunogenic cell death. Suic

Ref: Nature Reviews Cancer Gene Therapy Oncolytic Mechanisms 2021; NCI Cancer Gene Therapy Targeted Killing; Molecular Therapy Oncolytic Viruses 2021.

Hemophilia gene therapy targets deficiency of:

Hemophilia A 1 in 5000 males and B 1 in 30000 males result null mutations coagulation cofactors FVIII 280 kDa glycoprotein encoded F8 Xq28 domains A1 A2 B A3 C1 C2 and FIX vitamin K dependent serine protease encoded F9 Xq27 gamma carboxyglutamic acid residues binding calcium phospholipid. Both assemble intrinsic tenase complex FVIIIa cofactor enhancing FIXa protease activity 200000-fold toward FX activation on phosphatidylserine-rich platelet surface accelerating thrombin burst fibrin clot formation. Deficiency prolongs aPTT causing hemarthrosis, muscle hematoma. Replacement requires frequent

Ref: NEJM Hemophilia Gene Therapy Nathwani 2022; FDA Hemgenix Roctavian Approvals; Alberts Cell Biology Coagulation Cascade Chap 20.

Which disease was among the first targets of gene therapy?

Adenosine deaminase deficiency autosomal recessive SCID became earliest successful gene therapy target due biological features favoring correction. Enzyme chromosome 20q13.12 deaminates adenosine to inosine and deoxyadenosine to deoxyinosine, deficiency leads accumulation deoxyadenosine converted deoxycytidine kinase to dATP elevated dATP allosterically inhibits ribonucleotide reductase essential dNTP synthesis DNA replication lymphocyte clonal expansion triggers apoptosis intrinsic pathway resulting absent T B NK cells. Lymphoid lineage provides selective advantage because corrected cells det

Ref: Lancet ADA First Gene Therapy NEJM 1990; NCBI SCID Gene Therapy History; NCERT Biotechnology Applications ADA Chapter 12.